Titre : Rites funéraires

Rites funéraires : Questions médicales fréquentes

Termes MeSH sélectionnés :

Oxaliplatin

Questions fréquentes et termes MeSH associés

Diagnostic 2

#1

Comment identifier un rite funéraire spécifique ?

L'identification se fait par l'analyse des symboles, des pratiques et des croyances culturelles.
Rites funéraires Culture
#2

Quels éléments caractérisent un rite funéraire ?

Les éléments incluent les rituels, les prières, les offrandes et les cérémonies d'enterrement.
Rites funéraires Cérémonies

Symptômes 2

#1

Quels sentiments peuvent émerger lors d'un rite funéraire ?

Les participants peuvent ressentir de la tristesse, de la colère, de la paix ou de la nostalgie.
Émotions Rites funéraires
#2

Comment le deuil se manifeste-t-il pendant un rite ?

Le deuil peut se manifester par des pleurs, des cris ou des comportements de commémoration.
Deuil Rites funéraires

Prévention 2

#1

Comment préparer un rite funéraire à l'avance ?

Il est conseillé de discuter des souhaits avec la famille et de rédiger des directives claires.
Planification Rites funéraires
#2

Quels documents sont nécessaires pour un rite funéraire ?

Les documents incluent le certificat de décès et les arrangements préalables si existants.
Documents légaux Rites funéraires

Traitements 2

#1

Quels soutiens psychologiques sont offerts lors des rites ?

Des conseillers ou des thérapeutes peuvent être présents pour aider les endeuillés.
Soutien psychologique Rites funéraires
#2

Comment les rites funéraires aident-ils au processus de deuil ?

Ils offrent un cadre pour exprimer la douleur et favoriser la mémoire du défunt.
Deuil Rites funéraires

Complications 2

#1

Quelles complications peuvent survenir lors d'un rite ?

Des conflits familiaux ou des désaccords sur les rituels peuvent survenir.
Conflits familiaux Rites funéraires
#2

Comment gérer les émotions intenses lors d'un rite ?

Il est important d'avoir un soutien émotionnel et de permettre l'expression des sentiments.
Soutien émotionnel Rites funéraires

Facteurs de risque 2

#1

Quels facteurs influencent les rites funéraires ?

Les facteurs incluent la culture, la religion, et les traditions familiales.
Culture Rites funéraires
#2

Comment le contexte social affecte-t-il les rites ?

Le contexte social peut déterminer la manière dont les rites sont perçus et pratiqués.
Contexte social Rites funéraires
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Rites funéraires : Questions médicales les plus fréquentes", "headline": "Rites funéraires : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Rites funéraires : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-06-27", "dateModified": "2025-03-24", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Rites funéraires" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Anthropologie culturelle", "url": "https://questionsmedicales.fr/mesh/D000884", "about": { "@type": "MedicalCondition", "name": "Anthropologie culturelle", "code": { "@type": "MedicalCode", "code": "D000884", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "I01.076.201" } } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "Funérailles", "alternateName": "Burial", "url": "https://questionsmedicales.fr/mesh/D002048", "about": { "@type": "MedicalCondition", "name": "Funérailles", "code": { "@type": "MedicalCode", "code": "D002048", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "I01.076.201.450.550.150" } } }, { "@type": "MedicalWebPage", "name": "Crémation", "alternateName": "Cremation", "url": "https://questionsmedicales.fr/mesh/D055700", "about": { "@type": "MedicalCondition", "name": "Crémation", "code": { "@type": "MedicalCode", "code": "D055700", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "I01.076.201.450.550.175" } } }, { "@type": "MedicalWebPage", "name": "Embaumement", "alternateName": "Embalming", "url": "https://questionsmedicales.fr/mesh/D004615", "about": { "@type": "MedicalCondition", "name": "Embaumement", "code": { "@type": "MedicalCode", "code": "D004615", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "I01.076.201.450.550.250" } } } ], "about": { "@type": "MedicalCondition", "name": "Rites funéraires", "alternateName": "Funeral Rites", "code": { "@type": "MedicalCode", "code": "D005655", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "Megumi Kondo-Arita", "url": "https://questionsmedicales.fr/author/Megumi%20Kondo-Arita", "affiliation": { "@type": "Organization", "name": "President's Office, Global Center of Osaka Medical and Pharmaceutical University, Takatsuki, Japan." } }, { "@type": "Person", "name": "Carl B Becker", "url": "https://questionsmedicales.fr/author/Carl%20B%20Becker", "affiliation": { "@type": "Organization", "name": "Policy Science Unit, School of Medicine, Kyoto University, Kyoto, Japan." } }, { "@type": "Person", "name": "Livia Sani", "url": "https://questionsmedicales.fr/author/Livia%20Sani", "affiliation": { "@type": "Organization", "name": "SULISOM UR 3071, Université de Strasbourg, France." } }, { "@type": "Person", "name": "Marie-Frédérique Bacqué", "url": "https://questionsmedicales.fr/author/Marie-Fr%C3%A9d%C3%A9rique%20Bacqu%C3%A9", "affiliation": { "@type": "Organization", "name": "SULISOM UR 3071, Université de Strasbourg, France." } }, { "@type": "Person", "name": "Yozo Taniyama", "url": "https://questionsmedicales.fr/author/Yozo%20Taniyama", "affiliation": { "@type": "Organization", "name": "Department of Religious Studies, Tohoku University, Sendai 980-8576, Japan." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "Oxaliplatin (3 months", "datePublished": "2022-06-30", "url": "https://questionsmedicales.fr/article/35772045", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1200/JCO.21.02962" } }, { "@type": "ScholarlyArticle", "name": "Interactions with DNA Models of the Oxaliplatin Analog (", "datePublished": "2024-07-05", "url": "https://questionsmedicales.fr/article/39000496", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.3390/ijms25137392" } }, { "@type": "ScholarlyArticle", "name": "Upfront Modified Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan Plus Panitumumab Versus Fluorouracil, Leucovorin, and Oxaliplatin Plus Panitumumab for Patients With", "datePublished": "2022-06-06", "url": "https://questionsmedicales.fr/article/35666229", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1200/JCO.22.00839" } }, { "@type": "ScholarlyArticle", "name": "Unusual stroke-like symptoms with oxaliplatin use.", "datePublished": "2023-06-15", "url": "https://questionsmedicales.fr/article/37323007", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1177/10781552231181525" } }, { "@type": "ScholarlyArticle", "name": "Adjuvant Capecitabine and Oxaliplatin for Elderly Patients with Colorectal Cancer.", "datePublished": "2022-10-17", "url": "https://questionsmedicales.fr/article/36252550", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1159/000527012" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Sciences sociales", "item": "https://questionsmedicales.fr/mesh/D012942" }, { "@type": "ListItem", "position": 3, "name": "Anthropologie", "item": "https://questionsmedicales.fr/mesh/D000883" }, { "@type": "ListItem", "position": 4, "name": "Anthropologie culturelle", "item": "https://questionsmedicales.fr/mesh/D000884" }, { "@type": "ListItem", "position": 5, "name": "Rites funéraires", "item": "https://questionsmedicales.fr/mesh/D005655" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Rites funéraires - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Rites funéraires", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-10", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Rites funéraires", "description": "Comment identifier un rite funéraire spécifique ?\nQuels éléments caractérisent un rite funéraire ?", "url": "https://questionsmedicales.fr/mesh/D005655?mesh_terms=Oxaliplatin#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Rites funéraires", "description": "Quels sentiments peuvent émerger lors d'un rite funéraire ?\nComment le deuil se manifeste-t-il pendant un rite ?", "url": "https://questionsmedicales.fr/mesh/D005655?mesh_terms=Oxaliplatin#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Rites funéraires", "description": "Comment préparer un rite funéraire à l'avance ?\nQuels documents sont nécessaires pour un rite funéraire ?", "url": "https://questionsmedicales.fr/mesh/D005655?mesh_terms=Oxaliplatin#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Rites funéraires", "description": "Quels soutiens psychologiques sont offerts lors des rites ?\nComment les rites funéraires aident-ils au processus de deuil ?", "url": "https://questionsmedicales.fr/mesh/D005655?mesh_terms=Oxaliplatin#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Rites funéraires", "description": "Quelles complications peuvent survenir lors d'un rite ?\nComment gérer les émotions intenses lors d'un rite ?", "url": "https://questionsmedicales.fr/mesh/D005655?mesh_terms=Oxaliplatin#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Rites funéraires", "description": "Quels facteurs influencent les rites funéraires ?\nComment le contexte social affecte-t-il les rites ?", "url": "https://questionsmedicales.fr/mesh/D005655?mesh_terms=Oxaliplatin#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment identifier un rite funéraire spécifique ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "L'identification se fait par l'analyse des symboles, des pratiques et des croyances culturelles." } }, { "@type": "Question", "name": "Quels éléments caractérisent un rite funéraire ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "Les éléments incluent les rituels, les prières, les offrandes et les cérémonies d'enterrement." } }, { "@type": "Question", "name": "Quels sentiments peuvent émerger lors d'un rite funéraire ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "Les participants peuvent ressentir de la tristesse, de la colère, de la paix ou de la nostalgie." } }, { "@type": "Question", "name": "Comment le deuil se manifeste-t-il pendant un rite ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "Le deuil peut se manifester par des pleurs, des cris ou des comportements de commémoration." } }, { "@type": "Question", "name": "Comment préparer un rite funéraire à l'avance ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "Il est conseillé de discuter des souhaits avec la famille et de rédiger des directives claires." } }, { "@type": "Question", "name": "Quels documents sont nécessaires pour un rite funéraire ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Les documents incluent le certificat de décès et les arrangements préalables si existants." } }, { "@type": "Question", "name": "Quels soutiens psychologiques sont offerts lors des rites ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Des conseillers ou des thérapeutes peuvent être présents pour aider les endeuillés." } }, { "@type": "Question", "name": "Comment les rites funéraires aident-ils au processus de deuil ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "Ils offrent un cadre pour exprimer la douleur et favoriser la mémoire du défunt." } }, { "@type": "Question", "name": "Quelles complications peuvent survenir lors d'un rite ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Des conflits familiaux ou des désaccords sur les rituels peuvent survenir." } }, { "@type": "Question", "name": "Comment gérer les émotions intenses lors d'un rite ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Il est important d'avoir un soutien émotionnel et de permettre l'expression des sentiments." } }, { "@type": "Question", "name": "Quels facteurs influencent les rites funéraires ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "Les facteurs incluent la culture, la religion, et les traditions familiales." } }, { "@type": "Question", "name": "Comment le contexte social affecte-t-il les rites ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Le contexte social peut déterminer la manière dont les rites sont perçus et pratiqués." } } ] } ] }
Dr Olivier Menir

Contenu validé par Dr Olivier Menir

Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale


Validation scientifique effectuée le 24/03/2025

Contenu vérifié selon les dernières recommandations médicales

Auteurs principaux

Megumi Kondo-Arita

4 publications dans cette catégorie

Affiliations :
  • President's Office, Global Center of Osaka Medical and Pharmaceutical University, Takatsuki, Japan.

Livia Sani

3 publications dans cette catégorie

Affiliations :
  • SULISOM UR 3071, Université de Strasbourg, France.

Marie-Frédérique Bacqué

3 publications dans cette catégorie

Affiliations :
  • SULISOM UR 3071, Université de Strasbourg, France.

Yozo Taniyama

3 publications dans cette catégorie

Affiliations :
  • Department of Religious Studies, Tohoku University, Sendai 980-8576, Japan.

Shinya Yamada

3 publications dans cette catégorie

Affiliations :
  • National Museum of Japanese History, Sakura 285-8502, Japan.

Kayoko Yamamoto

3 publications dans cette catégorie

Affiliations :
  • Department of Nursing, Tenri Health Care University, Tenri 632-0018, Japan.

Jacques Cherblanc

2 publications dans cette catégorie

Affiliations :
  • Human and Social Sciences, Université du Québec à Chicoutimi(UQAC), Saguenay, Canada.
Publications dans "Rites funéraires" :

Donna M Wilson

2 publications dans cette catégorie

Affiliations :
  • Registered Nurse, Professor, Faculty of Nursing, University of Alberta, Canada.
Publications dans "Rites funéraires" :

Suzanne Rainsford

2 publications dans cette catégorie

Affiliations :
  • Rural Clinical School, Australian National University Medical School, Australia.
Publications dans "Rites funéraires" :

Bruce Rumbold

2 publications dans cette catégorie

Affiliations :
  • Public Health Palliative Care Unit, School of Psychology and Public Health, La Trobe University, Melbourne, Australia.

Jennifer Lowe

2 publications dans cette catégorie

Affiliations :
  • Public Health Palliative Care Unit, School of Psychology and Public Health, La Trobe University, Melbourne, Australia.

Samar M Aoun

2 publications dans cette catégorie

Affiliations :
  • Public Health Palliative Care Unit, School of Psychology and Public Health, La Trobe University, Melbourne, Australia.
  • The Perron Institute for Neurological and Translational Science, Perth, Australia.

Iñigo Lorenzo Ruiz

2 publications dans cette catégorie

Affiliations :
  • Nursing Department, Faculty of Medicine and Nursing, University of the Basque Country UPV/EHU,Sarriena, Leioa, Spain.
  • BioCruces-Bizkaia Health Research Institute, Barakaldo, Spain.

Selom Komlan Noussoukpoe

2 publications dans cette catégorie

Affiliations :
  • Equipe de recherché de l'Association Togolaise pour le Bien-Etre Familial (ATBEF).

Willis Gwenzi

2 publications dans cette catégorie

Affiliations :
  • Biosystems and Environmental Engineering Research Group, Department of Soil Science and Agricultural Engineering, Faculty of Agriculture, University of Zimbabwe, P.O. Box MP167, Mount Pleasant, Harare, Zimbabwe. Electronic address: wgwenzi@agric.uz.ac.zw.

Noriko Sasaki

2 publications dans cette catégorie

Affiliations :
  • Department of Healthcare Economics and Quality Management, Graduate School of Medicine, Kyoto University, Kyoto 606-8501, Japan.

Veronica E Galimberti

1 publication dans cette catégorie

Affiliations :
  • Department of Immunobiology, Yale University School of Medicine, New Haven, CT.
  • Department of Neurology, Yale University School of Medicine, New Haven, CT.
Publications dans "Rites funéraires" :

Carla V Rothlin

1 publication dans cette catégorie

Affiliations :
  • Department of Immunobiology, Yale University School of Medicine, New Haven, CT.
  • Department of Pharmacology, Yale University School of Medicine, New Haven, CT.
Publications dans "Rites funéraires" :

Sourav Ghosh

1 publication dans cette catégorie

Affiliations :
  • Department of Neurology, Yale University School of Medicine, New Haven, CT.
  • Department of Pharmacology, Yale University School of Medicine, New Haven, CT.
Publications dans "Rites funéraires" :

Sources (746 au total)

Oxaliplatin (3 months

The combination of oxaliplatin and fluoropyrimidine for 6 months is one of the standard options for adjuvant therapy for high-risk stage II and III colorectal cancers (CRCs). The optimal duration of o... This open-label, randomized, phase III, noninferiority trial randomly assigned patients with high-risk stage II and III CRC to 3 and 6 months of oxaliplatin with 6 months of fluoropyrimidine groups (3... In total, 1,788 patients were randomly assigned to the 6-month (n = 895) and 3-month (n = 893) arms, and 83.6% in the 6-month arm and 85.7% in the 3-month arm completed the treatment. The neuropathy r... This study suggests that adding 3 months of oxaliplatin to 6 months of capecitabine could be considered an alternative adjuvant treatment for stage III CRC (ClinicalTrials.gov identifier: NCT01092481)...

Upfront Modified Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan Plus Panitumumab Versus Fluorouracil, Leucovorin, and Oxaliplatin Plus Panitumumab for Patients With

To verify whether the intensification of the upfront chemotherapy backbone with a modified schedule of modified fluorouracil, leucovorin, oxaliplatin, and irinotecan (mFOLFOXIRI) increases the activit... TRIPLETE was a prospective, open-label, phase III trial in which previously untreated patients with unresectable... From September 2017 to September 2021, 435 patients were enrolled (control group/experimental group: 217/218) in 57 Italian sites. One hundred sixty (73%) patients treated with mFOLFOXIRI plus panitum... The intensification of the upfront chemotherapy backbone in combination with panitumumab does not provide additional benefit in terms of treatment activity at the price of increased gastrointestinal t...

Unusual stroke-like symptoms with oxaliplatin use.

Oxaliplatin has become the mainstay of treatment for many cancers, but its use can be accompanied by unusual side effects.... We describe herein a 74-year-old patient with pancreatic cancer who developed severe motor weakness affecting lower extremities after starting treatment with oxaliplatin on three separate occasions. O... Oxaliplatin had to be discontinued due to suboptimal tolerance and a short-lived clinical response. After discontinuation of oxaliplatin, she did not experience any more similar symptoms. A score of 9... Rare reports of stroke-like events have previously been described with oxaliplatin. While the exact mechanism of these phenomena is not known, alterations in neuronal sodium channels might be involved...

Adjuvant Capecitabine and Oxaliplatin for Elderly Patients with Colorectal Cancer.

Adjuvant chemotherapy improves the prognosis of patients with colorectal cancer (CRC) following radical resection. However, the safety and efficacy of oxaliplatin-based chemotherapeutic regimens for e... We examined 138 Japanese patients who received adjuvant CAPOX therapy for high-risk stage II or III CRC between July 2010 and June 2021 at our hospital. Patients were divided according to an age of 70... Twenty-three patients (17%) were ≥70 years old. Male patients were predominant in the ≥70 years group (p = 0.006). Patients ≥70 years old had more comorbidities (diabetes, p = 0.014; cardiovascular di... Adjuvant CAPOX therapy was tolerable in elderly Japanese patients. The prognosis of elderly patients with stage III CRC was similar to that of their younger counterparts. Advanced age itself may not b...

CHK2 activation contributes to the development of oxaliplatin resistance in colorectal cancer.

Colorectal cancer (CRC), the most common cancer type, causes high morbidity and mortality. Patients who develop drug resistance to oxaliplatin-based regimens have short overall survival. Thus, identif... A proteomic screen was performed to reveal altered protein kinase phosphorylation in oxaliplatin-resistant (OR) CRC tumour spheroids. The function of CHK2 was characterised using several biochemical t... We revealed that the level of phospho-CHK2(Thr68) was elevated in OR CRC cells and in ~30% of tumour samples from patients with OR CRC. We demonstrated that oxaliplatin activated several phosphatidyli... Our findings suggest that CHK2 activity is critical for modulating oxaliplatin response and that CHK2 is a potential therapeutic target for OR CRC....